About Lantern Pharma
Lantern Pharma is a company based in Dallas (United States) founded in 2013. It operates as a AI-as-a-Service and Professional Services. Lantern Pharma has raised $7.12 million across 5 funding rounds from investors including United States Department of Agriculture, Bios Partners and Green Park & Golf Ventures. The company has 24 employees as of December 31, 2024. Lantern Pharma offers products and services including LP-300 and RADR Platform. Lantern Pharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Natera, among others.
- Headquarter Dallas, United States
- Employees 24 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lantern Pharma Inc.
-
Annual Revenue
Not available
-
Net Profit
-$20.78 M (USD)-30.2as on Dec 31, 2024
-
EBITDA
-$22.03 M (USD)-24.42as on Dec 31, 2024
-
Total Equity Funding
$7.12 M (USD)
in 5 rounds
-
Latest Funding Round
$20 K (USD), Grant
Jan 03, 2022
- Investors
-
Employee Count
24
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lantern Pharma
Lantern Pharma is a publicly listed company on the NASDAQ with ticker symbol LTRN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lantern Pharma
Lantern Pharma offers a comprehensive portfolio of products and services, including LP-300 and RADR Platform.
Investigational drug for non-small cell lung cancer treatment.
AI platform for oncology drug development and testing.
People of Lantern Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Lantern Pharma
Lantern Pharma has successfully raised a total of $7.12M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $20 thousand completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lantern Pharma
Lantern Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include United States Department of Agriculture, Bios Partners and Green Park & Golf Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided by Bios Partners for biotech innovation.
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are made in medical startups.
|
Locked | Locked | Locked | |
|
Healthcare startups are accelerated via a 12-week funding program.
|
Locked | Locked | Locked |
Investor details for Lantern Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lantern Pharma
Investment portfolio details for Lantern Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lantern Pharma
Detailed financials for Lantern Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lantern Pharma Comparisons
Peer comparison for Lantern Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lantern Pharma
Lantern Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Natera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of Lantern Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lantern Pharma
Complete news archive for Lantern Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lantern Pharma
Lantern Pharma was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Lantern Pharma is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Lantern Pharma is a funded company, having raised a total of $7.12M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lantern Pharma is 24.
Lantern Pharma is engaged in transforming oncology drug discovery and development through the use of artificial intelligence, machine learning, and genomics. The company is dedicated to delivering precision therapies for cancer patients across multiple indications. Their portfolio includes three lead drug candidates and an ADC program targeting 12 cancer types. Clinical trials, such as the Harmonic Phase 2 study, are conducted to evaluate investigational drugs. Costs and timelines are aimed to be significantly reduced through their proprietary RADR platform, one of the largest AI-powered platforms for oncology therapeutics.
Lantern Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Lantern Pharma offers LP-300 and RADR Platform.
Yes, Lantern Pharma is publicly traded on NASDAQ under the ticker symbol LTRN.
Lantern Pharma has 4 investors. Key investors include United States Department of Agriculture, Bios Partners, Green Park & Golf Ventures, and Health Wildcatters.
The ticker symbol of Lantern Pharma is LTRN on NASDAQ.